Български
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Beige Fat, Energy, and the Natriuretic Peptide System

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
Линкът е запазен в клипборда
СъстояниеНабиране
Спонсори
VA Office of Research and Development
Сътрудници
Vanderbilt University Medical Center

Ключови думи

Резюме

Obese individuals experience an increased risk of cardiovascular and metabolic diseases. Evidence from genetic studies indicate that the natriuretic peptide (NP) system may protect against these diseases. NP levels differ by obesity status and race has not been established in humans. Thus, the investigators propose a study in which will quantify adipose tissue gene expression and energy expenditure in states of NP deficiency in humans. The overarching postulate is that obese and black individuals have NP deficiencies that contribute to less beige adipose tissue and lower energy expenditure.

Описание

Obesity represents a serious public health burden. Obese individuals experience increased risk of cardiovascular and metabolic cardiometabolic disease, including insulin diabetes, resistance, hypertension, and dyslipidemia. Obesity and obesity-associated cardiometabolic dysfunction are significant contributors to morbidity and mortality in Veterans. This indicates that obesity and cardiometabolic dysfunction are complex and multifactorial, and suggests that there are additional factors that contribute to the pathogenesis of obesity and its associated cardiometabolic risk that have been discovered. Moreover, some of the pharmacologic therapies for obesity can have adverse cardiovascular effects. Thus, it is crucial to improve the understanding of the multiple pathways contributing to the pathogenesis of obesity and obesity-associated cardiometabolic risk, including the identification of novel relevant pathways, in order to develop more effective treatments for these diseases. The proposed work will form a foundation for future high-impact studies of mechanisms for adiposity and cardiometabolic disease.

Дати

Последна проверка: 03/31/2020
Първо изпратено: 04/13/2020
Очаквано записване подадено: 04/20/2020
Първо публикувано: 04/21/2020
Изпратена последна актуализация: 04/20/2020
Последна актуализация публикувана: 04/21/2020
Действителна начална дата на проучването: 04/12/2020
Приблизителна дата на първично завършване: 06/29/2023
Очаквана дата на завършване на проучването: 06/29/2023

Състояние или заболяване

Obesity

Фаза

-

Групи за ръце

ArmИнтервенция / лечение
obese and lean individuals
obese and lean individuals

Критерии за допустимост

Възрасти, отговарящи на условията за проучване 18 Years Да се 18 Years
Полове, допустими за проучванеAll
Метод за вземане на пробиProbability Sample
Приема здрави доброволциДа
Критерии

Inclusion Criteria:

- Men and women ages 18-55 years

- Body Mass Index (BMI) >= 18.5 and <25 kg/m2 (lean), or BMI 30 kg/m2 (obese)

Exclusion Criteria:

- Significant pulmonary, liver, or renal disease

- Heart failure (any type) or unstable coronary artery disease

- Diabetes Mellitus (Types 1 and 2)

- Thyroid dysfunction

- Active malignancy

- Chronic inflammatory diseases, such as inflammatory bowel disease, hepatitis, rheumatoid arthritis

- Postmenopausal status (for women)

- Current use of medications likely to affect energy homeostasis, including glucocorticoids, amphetamines, and beta blockers

- Currently pregnant or breastfeeding, or unwilling to avoid becoming pregnant or breastfeeding during study duration

- Significant claustrophobia that would prevent the use of the metabolic cart as part of the study protocol

- Hemoglobin A1c (HbA1c) >= 6.5%

- Liver Function Tests (LFTs) elevated >3x upper limit of normal

- Estimated Glomerular Filtration Rate (eGFR) <40 ml/min

- Currently abnormal thyroid stimulating hormone (TSH)

Резултат

Първични изходни мерки

1. adipose tissue gene expression of UCP1 (Uncoupling Protein 1)- differences by obesity status [Study Day 1]

Primary endpoint is adipose tissue gene expression of UCP1 (Uncoupling Protein 1)- differences by obesity status.

Вторични изходни мерки

1. Associations of adipose tissue gene expression of UCP1 with natriuretic peptide markers [Study Day 1]

The investigators will determine associations of adipose tissue gene expression of UCP1 with natriuretic peptide markers (natriuretic peptide receptor gene expression in adipose tissue, and circulating natriuretic peptide levels)

2. adipose tissue gene expression of UCP1 (Uncoupling Protein 1)- differences by race [Study Day 1]

The investigators will determine adipose tissue gene expression of UCP1 (Uncoupling Protein 1), and analyze differences by race (blacks compared with whites).

Присъединете се към нашата
страница във facebook

Най-пълната база данни за лечебни билки, подкрепена от науката

  • Работи на 55 езика
  • Билкови лекове, подкрепени от науката
  • Разпознаване на билки по изображение
  • Интерактивна GPS карта - маркирайте билките на място (очаквайте скоро)
  • Прочетете научни публикации, свързани с вашето търсене
  • Търсете лечебни билки по техните ефекти
  • Организирайте вашите интереси и бъдете в крак с научните статии, клиничните изследвания и патентите

Въведете симптом или болест и прочетете за билките, които биха могли да помогнат, напишете билка и вижте болестите и симптомите, срещу които се използва.
* Цялата информация се базира на публикувани научни изследвания

Google Play badgeApp Store badge